EQUILLIUM INC (EQ)
US29446K1060 - Common Stock
EQ gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While EQ seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, EQ is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
EQ had negative earnings in the past year.
EQ had a negative operating cash flow in the past year.
EQ had negative earnings in each of the past 5 years.
EQ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
EQ has a Return On Assets of -19.41%. This is in the better half of the industry: EQ outperforms 78.97% of its industry peers.
EQ's Return On Equity of -37.08% is fine compared to the rest of the industry. EQ outperforms 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.41% | ||
| ROE | -37.08% | ||
| ROIC | N/A |
ROA(3y)-50.57%
ROA(5y)-46.54%
ROE(3y)-104.42%
ROE(5y)-83.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EQ has more shares outstanding
The number of shares outstanding for EQ has been increased compared to 5 years ago.
EQ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
EQ has an Altman-Z score of -4.54. This is a bad value and indicates that EQ is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EQ (-4.54) is comparable to the rest of the industry.
There is no outstanding debt for EQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.54 |
ROIC/WACCN/A
WACC12.06%
2.3 Liquidity
EQ has a Current Ratio of 2.08. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.08, EQ is doing worse than 75.40% of the companies in the same industry.
EQ has a Quick Ratio of 2.08. This indicates that EQ is financially healthy and has no problem in meeting its short term obligations.
EQ has a worse Quick ratio (2.08) than 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 2.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.83% over the past year.
The Revenue has grown by 26.25% in the past year. This is a very strong growth!
EPS 1Y (TTM)52.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)26.25%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.83%
3.2 Future
Based on estimates for the next years, EQ will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.71% on average per year.
EQ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.27% yearly.
EPS Next Y-89.27%
EPS Next 2Y-83.68%
EPS Next 3Y-64.81%
EPS Next 5Y-16.71%
Revenue Next Year3.25%
Revenue Next 2Y-41.42%
Revenue Next 3Y-26.42%
Revenue Next 5Y21.27%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EQ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EQ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as EQ's earnings are expected to decrease with -64.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.68%
EPS Next 3Y-64.81%
5. Dividend
5.1 Amount
No dividends for EQ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EQUILLIUM INC
NASDAQ:EQ (11/21/2024, 8:24:56 PM)
0.72
+0 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.51M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.41% | ||
| ROE | -37.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.08 | ||
| Quick Ratio | 2.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)52.83%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-89.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.25%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y